Wegovy was made accessible in Europe’s most obese country on Sept. 4, in what Novo called a “managed and confined start”. The Norwegian Medicines Agency stated in January 2023 it wouldn't subsidise the drug, stating the price would be much too significant in relation for the documented overall health consequences. https://jenningsx581jqx3.bloggactif.com/profile